04.08 11:00 | dpa-AFX: Weekly Biotech Buzz: FGEN Cuts Jobs, FDA OKs ADAP's Groundbreaking Cell Therapy, ME Rebuffs CEO Bid |
02.08 13:48 | dpa-AFX: *DZ BANK RAISES FAIR VALUE FOR BIOGEN TO 219 (214) USD - 'HOLD' |
02.08 13:48 | dpa-AFX: *DZ BANK HEBT FAIREN WERT FÜR BIOGEN AUF 219 (214) USD - 'HALTEN' |
01.08 13:31 | dpa-AFX: Biogen Q2 Results Top Estimates; Boosts FY24 Outlook |
01.08 13:17 | dpa-AFX: *BIOGEN Q2 TOTAL REVENUE $2.465 BLN; NET INCOME ATTRIBUTABLE TO BIOGEN $583.6 MLN |
01.08 13:16 | dpa-AFX: *BIOGEN NOW SEES FY OPERATING INCOME TO GROW AT A MID- TO HIGH-TEEN PERCENTAGE |
01.08 13:15 | dpa-AFX: *BIOGEN NOW SEES FY TOTAL REVENUE TO DECLINE BY A LOW-SINGLE DIGIT PERCENTAGE |
01.08 13:15 | dpa-AFX: *BIOGEN LIFTS FY VIEW: NOW SEES NON-GAAP EPS TO BE BETWEEN $15.75 AND $16.25 |
01.08 13:05 | dpa-AFX: *BIOGEN Q2 GAAP EPS $4.00; NON-GAAP EPS $5.28 |
30.07 23:15 | dpa-AFX: GNW-Adhoc: New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at The Alzheimer's Association International |
30.07 16:10 | dpa-AFX: Biogen, Beckman Coulter, Fujirebio To Develop Tau Pathology Blood Test For Alzheimer's Disease |
30.07 14:50 | dpa-AFX: *BIOGEN, BECKMAN COULTER AND FUJIREBIO TO DEVELOP BLOOD-BASED BIOMARKERS FOR TAU PATHOLOGY IN AD |
30.07 13:30 | dpa-AFX: GNW-Adhoc: Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer's Disease |
26.07 15:47 | dpa-AFX: *BIOGEN -5,2% - EMA VERWEIGERT ZULASSUNG EINES ALZHEIMER-MITTELS |
26.07 15:33 | dpa-AFX: Biogen Falls After Receiving Negative Opinion From CHMP For Lecanemab For Early Alzheimer's Disease |
26.07 15:04 | dpa-AFX: ROUNDUP: EU-Behörde lehnt Empfehlung von Alzheimer-Medikament ab |
26.07 15:04 | ROUNDUP: EU-Behörde lehnt Empfehlung von Alzheimer-Medikament ab |
26.07 14:59 | dpa-AFX: ROUNDUP: EU-Behörde lehnt Empfehlung von Alzheimer-Medikament ab |
26.07 13:30 | dpa-AFX: *EISAI AND BIOGEN : CHMP ISSUES NEGATIVE OPINION ON LECANEMAB FOR EARLY ALZHEIMER'S DISEASE |
26.07 13:20 | dpa-AFX: GNW-Adhoc: Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union |
|